1008 related articles for article (PubMed ID: 28702892)
21. Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
Lesniak D; Sabri S; Xu Y; Graham K; Bhatnagar P; Suresh M; Abdulkarim B
PLoS One; 2013; 8(8):e71987. PubMed ID: 23991019
[TBL] [Abstract][Full Text] [Related]
22. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
Boulbes DR; Chauhan GB; Jin Q; Bartholomeusz C; Esteva FJ
Breast Cancer Res Treat; 2015 Jun; 151(3):501-13. PubMed ID: 25971596
[TBL] [Abstract][Full Text] [Related]
23. Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer.
Tian J; Hachim MY; Hachim IY; Dai M; Lo C; Raffa FA; Ali S; Lebrun JJ
Sci Rep; 2017 Jan; 7():40258. PubMed ID: 28054666
[TBL] [Abstract][Full Text] [Related]
24. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
[TBL] [Abstract][Full Text] [Related]
25. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
26. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
27. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
Li Y; Chu J; Feng W; Yang M; Zhang Y; Zhang Y; Qin Y; Xu J; Li J; Vasilatos SN; Fu Z; Huang Y; Yin Y
FASEB J; 2019 Apr; 33(4):4851-4865. PubMed ID: 30620624
[TBL] [Abstract][Full Text] [Related]
28. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
[TBL] [Abstract][Full Text] [Related]
29. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
[TBL] [Abstract][Full Text] [Related]
30. Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study.
Kang SA; Guan JS; Tan HJ; Chu T; Thike AA; Bernadó C; Arribas J; Wong CY; Tan PH; Gudi M; Putti TC; Sohn J; Lim SH; Lee SC; Lim YP
Clin Cancer Res; 2019 Apr; 25(8):2588-2600. PubMed ID: 30593516
[TBL] [Abstract][Full Text] [Related]
31. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Choi HJ; Jin S; Cho H; Won HY; An HW; Jeong GY; Park YU; Kim HY; Park MK; Son T; Min KW; Jang KS; Oh YH; Lee JY; Kong G
EMBO Rep; 2019 Oct; 20(10):e48058. PubMed ID: 31468695
[TBL] [Abstract][Full Text] [Related]
32. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
34. A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
Wu Y; Tran T; Dwabe S; Sarkissyan M; Kim J; Nava M; Clayton S; Pietras R; Farias-Eisner R; Vadgama JV
Breast Cancer Res Treat; 2017 Jun; 163(3):449-460. PubMed ID: 28337662
[TBL] [Abstract][Full Text] [Related]
35. Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
Holmes FA; Espina V; Liotta LA; Nagarwala YM; Danso M; McIntyre KJ; Osborne CR; Anderson T; Krekow L; Blum JL; Pippen J; Florance A; Mahoney J; O'Shaughnessy JA
BMC Res Notes; 2013 Dec; 6():507. PubMed ID: 24304724
[TBL] [Abstract][Full Text] [Related]
36. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
37. Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
Wang RX; Chen S; Jin X; Chen CM; Shao ZM
Breast Cancer Res Treat; 2017 Jan; 161(2):259-267. PubMed ID: 27885439
[TBL] [Abstract][Full Text] [Related]
38. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S; Pavlick AC; Contreras A; Nuciforo P; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Wolff AC; Krop IE; Fuqua SAW; Prat A; Hilsenbeck SG; Weigelt B; Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
Ann Oncol; 2019 Jun; 30(6):927-933. PubMed ID: 30903140
[TBL] [Abstract][Full Text] [Related]
39. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy.
Nawa M; Osada S; Morimitsu K; Nonaka K; Futamura M; Kawaguchi Y; Yoshida K
Anticancer Res; 2012 Jan; 32(1):13-9. PubMed ID: 22213283
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Gayle SS; Arnold SL; O'Regan RM; Nahta R
Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
